Date: 14.1.2011
The blood test could mean that 98% of invasive procedures could be avoided, say the authors. The test uses the latest DNA technology to analyse genetic components in the mother's blood that indicate whether the fetus has Down's.
Women in high risk groups tend to undergo a combination of scans and hormone level tests in order to determine if they need to have an invasive test such as amniocentesis or chorionic villus sampling.
The results show that the test is highly accurate in detecting Down's syndrome in unborn babies and does not give false negative results.
In this way the number of women requiring invasive procedures can be reduced.
Original Paper:
R. W. K. Chiu, R. Akolekar, Y. W. L. Zheng, T. Y. Leung, H. Sun, K. C. A. Chan, F. M. F. Lun, A. T. J. I. Go, E. T. Lau, W. W. K. To, W. C. Leung, R. Y. K. Tang, S. K. C. Au-Yeung, H. Lam, Y. Y. Kung, X. Zhang, J. M. G. van Vugt, R. Minekawa, M. H. Y. Tang, J. Wang, C. B. M. Oudejans, T. K. Lau, K. H. Nicolaides, Y. M. D. Lo. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ, 2011; 342 (jan11 1): c7401 DOI: 10.1136/bmj.c7401
Source:
http://www.sciencedaily.com/releases/2011/01/110111184135.htm
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Masaryk University - Masaryk University in Brno
Biotechnology - Biotech information at Wikipedia
The first eco-friendly fluorescent artificial seed for monitoring soil temperature by using drones
Meet pAblo·pCasso: A new leap in CRISPR technologies for next-gen genome engineering